JEIL PHARMACEUTICAL secures South Korea rights for Shionogis antibiotic Petrozajoo JEIL PHARMACEUTICAL prepares to enhance ...

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan, where it will be sold by licensee Shionogi.

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

Shionogi & Co ((JP:4507)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Shionogi & Co. revealed a mixed sentiment, characterized by ...

The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...

Founded in 1878 and based in Osaka, Japan, Shionogi is a drug-discovery-based pharmaceutical company with more than 5,500 employees and operations around the globe, including offices in the US ...

Iwasaki attributed the decision to shifts in business strategies and emphasized that Shionogi will focus on new drug launches in China, including Phase 3-completed Cefiderocol and Naldemedine.

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...

Shionogi Inc., 300 Campus Drive, Florham Park, NJ 07932 USA Antimicrobial resistance (AMR) has become a serious threat to the effective prevention and treatment of infections caused by bacteria ...